338 related articles for article (PubMed ID: 30010800)
1. Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition.
Panahi M; Papanikolaou A; Torabi A; Zhang JG; Khan H; Vazir A; Hasham MG; Cleland JGF; Rosenthal NA; Harding SE; Sattler S
Cardiovasc Res; 2018 Sep; 114(11):1445-1461. PubMed ID: 30010800
[TBL] [Abstract][Full Text] [Related]
2. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure.
Hartman MHT; Groot HE; Leach IM; Karper JC; van der Harst P
Trends Cardiovasc Med; 2018 Aug; 28(6):369-379. PubMed ID: 29519701
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.
Huang S; Frangogiannis NG
Br J Pharmacol; 2018 May; 175(9):1377-1400. PubMed ID: 29394499
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
Jafree E; Del Buono MG; Canada JM; Carbone S; Kron J; Arena R; Van Tassell B; Abbate A; Trankle CR
J Cardiovasc Pharmacol; 2024 Jun; 83(6):522-530. PubMed ID: 37815298
[TBL] [Abstract][Full Text] [Related]
5. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities.
Andreadou I; Cabrera-Fuentes HA; Devaux Y; Frangogiannis NG; Frantz S; Guzik T; Liehn EA; Gomes CPC; Schulz R; Hausenloy DJ
Cardiovasc Res; 2019 Jun; 115(7):1117-1130. PubMed ID: 30825305
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 blockade in cardiovascular diseases: a clinical update.
Buckley LF; Abbate A
Eur Heart J; 2018 Jun; 39(22):2063-2069. PubMed ID: 29584915
[TBL] [Abstract][Full Text] [Related]
7. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities.
Ong SB; Hernández-Reséndiz S; Crespo-Avilan GE; Mukhametshina RT; Kwek XY; Cabrera-Fuentes HA; Hausenloy DJ
Pharmacol Ther; 2018 Jun; 186():73-87. PubMed ID: 29330085
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).
Van Tassell BW; Canada J; Carbone S; Trankle C; Buckley L; Oddi Erdle C; Abouzaki NA; Dixon D; Kadariya D; Christopher S; Schatz A; Regan J; Viscusi M; Del Buono M; Melchior R; Mankad P; Lu J; Sculthorpe R; Biondi-Zoccai G; Lesnefsky E; Arena R; Abbate A
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141858
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction.
de Kleijn DPV; Chong SY; Wang X; Yatim SMJM; Fairhurst AM; Vernooij F; Zharkova O; Chan MY; Foo RSY; Timmers L; Lam CSP; Wang JW
Cardiovasc Res; 2019 Oct; 115(12):1791-1803. PubMed ID: 30830156
[TBL] [Abstract][Full Text] [Related]
10. Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
Takahashi M
J Cardiovasc Pharmacol; 2019 Sep; 74(3):188-193. PubMed ID: 31356542
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
Buckley LF; Libby P
J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
[TBL] [Abstract][Full Text] [Related]
12. The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function.
Skorska A; von Haehling S; Ludwig M; Lux CA; Gaebel R; Kleiner G; Klopsch C; Dong J; Curato C; Altarche-Xifró W; Slavic S; Unger T; Steinhoff G; Li J; David R
J Cell Mol Med; 2015 Aug; 19(8):1975-85. PubMed ID: 25991381
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).
Van Tassell BW; Buckley LF; Carbone S; Trankle CR; Canada JM; Dixon DL; Abouzaki N; Oddi-Erdle C; Biondi-Zoccai G; Arena R; Abbate A
Clin Cardiol; 2017 Sep; 40(9):626-632. PubMed ID: 28475816
[TBL] [Abstract][Full Text] [Related]
14. The role of intravenous immunoglobulin in the treatment of chronic heart failure.
Aukrust P; Yndestad A; Ueland T; Damås JK; Frøland SS; Gullestad L
Int J Cardiol; 2006 Sep; 112(1):40-5. PubMed ID: 16893578
[TBL] [Abstract][Full Text] [Related]
15. CD8
Ilatovskaya DV; Pitts C; Clayton J; Domondon M; Troncoso M; Pippin S; DeLeon-Pennell KY
Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H581-H596. PubMed ID: 31322426
[TBL] [Abstract][Full Text] [Related]
16. Potential novel pharmacological therapies for myocardial remodelling.
Landmesser U; Wollert KC; Drexler H
Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
[TBL] [Abstract][Full Text] [Related]
17. Targeting interleukin-1 in heart failure and inflammatory heart disease.
Van Tassell BW; Raleigh JM; Abbate A
Curr Heart Fail Rep; 2015 Feb; 12(1):33-41. PubMed ID: 25315037
[TBL] [Abstract][Full Text] [Related]
18. Targeting neuro-immune systems to achieve cardiac tissue repair following myocardial infarction: A review of therapeutic approaches from in-vivo preclinical to clinical studies.
Smith S; Ascione R
Pharmacol Ther; 2023 May; 245():108397. PubMed ID: 36996910
[TBL] [Abstract][Full Text] [Related]
19. NLRP3 Inflammasome in Cardioprotective Signaling.
Zuurbier CJ
J Cardiovasc Pharmacol; 2019 Oct; 74(4):271-275. PubMed ID: 31356546
[TBL] [Abstract][Full Text] [Related]
20. Cells of the Immune System in Cardiac Remodeling: Main Players in Resolution of Inflammation and Repair After Myocardial Infarction.
Kologrivova I; Shtatolkina M; Suslova T; Ryabov V
Front Immunol; 2021; 12():664457. PubMed ID: 33868315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
